These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18584582)

  • 21. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.
    Goebel M; Clemenz M; Unger T
    Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):615-29. PubMed ID: 17081084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telmisartan for the management of patients at high cardiovascular risk.
    Ruilope LM
    Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
    Weber MA
    Am J Cardiol; 2002 Jan; 89(2A):27A-33A. PubMed ID: 11835909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-clinical and clinical experience of telmisartan in cardiac remodelling.
    Verdecchia P
    J Int Med Res; 2005; 33 Suppl 1():12A-20A. PubMed ID: 16222896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.
    Liu W; Wang W; Song SW; Gu XF; Ma XJ; Su FY; Zhang H; Liu AJ; Su DF
    J Cardiovasc Pharmacol; 2011 Mar; 57(3):308-16. PubMed ID: 21266915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
    McFarlane SI
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1363-71. PubMed ID: 19900019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan improves endothelial function in patients with essential hypertension.
    Benndorf RA; Appel D; Maas R; Schwedhelm E; Wenzel UO; Böger RH
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):367-71. PubMed ID: 18049303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan for the reduction of cardiovascular morbidity and mortality.
    Verdecchia P; Angeli F; Gentile G; Mazzotta G; Reboldi G
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):151-61. PubMed ID: 22115399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures.
    Neldam S; Schumacher H; Guthrie R
    Adv Ther; 2012 Apr; 29(4):327-38. PubMed ID: 22477543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.
    Kobayashi K; Ohno Y; Takenaka T; Ikeda N; Okada H; Kanno Y; Suzuki H
    Clin Exp Hypertens; 2011; 33(2):100-5. PubMed ID: 21269058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal and vascular protective effects of telmisartan in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Sawada K
    Hypertens Res; 2006 Aug; 29(8):567-72. PubMed ID: 17137211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
    Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
    Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.